NPI: 1487639381 · SAINT PAUL, MN 55112 · Clinical Medical Laboratory · NPI assigned 12/13/2005
Authorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
| Authorized Official | WILLIAMS, KIMBERLY (VP) |
| NPI Enumeration Date | 12/13/2005 |
Other providers sharing the same authorized official: WILLIAMS, KIMBERLY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 186,062 | $3.57M |
| 2019 | 216,993 | $4.39M |
| 2020 | 150,471 | $3.32M |
| 2021 | 263,582 | $3.25M |
| 2022 | 335,339 | $3.73M |
| 2023 | 551,243 | $13.35M |
| 2024 | 491,541 | $16.12M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 450,763 | 322,753 | $15.28M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 125,141 | 109,125 | $10.24M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 186,714 | 124,975 | $8.95M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 64,119 | 51,520 | $4.22M |
| 83655 | 562,461 | 525,568 | $3.80M | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 32,987 | 14,885 | $2.90M |
| 80348 | 36,537 | 29,281 | $147K | |
| 80359 | 32,783 | 26,280 | $136K | |
| 80361 | 32,008 | 25,911 | $132K | |
| 80353 | 31,957 | 25,806 | $120K | |
| 80365 | 31,531 | 25,491 | $108K | |
| 80358 | 32,494 | 26,175 | $106K | |
| 80347 | 28,116 | 22,571 | $101K | |
| 80354 | 32,805 | 26,501 | $101K | |
| 80372 | 30,137 | 24,125 | $93K | |
| 85018 | 93,553 | 87,622 | $91K | |
| 80360 | 22,794 | 17,461 | $84K | |
| 80373 | 28,750 | 22,958 | $81K | |
| 80321 | 1,926 | 1,736 | $67K | |
| 80370 | 24,042 | 18,613 | $61K | |
| 80337 | 21,264 | 16,097 | $59K | |
| 80364 | 20,777 | 15,667 | $59K | |
| 80377 | 9,715 | 8,877 | $55K | |
| 80367 | 10,950 | 9,986 | $50K | |
| 80326 | 9,760 | 8,935 | $50K | |
| 80324 | 22,325 | 16,908 | $47K | |
| 80334 | 21,188 | 16,009 | $45K | |
| 80368 | 22,817 | 17,412 | $45K | |
| 80346 | 5,971 | 4,760 | $43K | |
| 80338 | 21,196 | 16,008 | $43K | |
| 80331 | 9,665 | 8,834 | $41K | |
| 80366 | 17,277 | 14,338 | $41K | |
| 80355 | 16,901 | 14,025 | $39K | |
| 80344 | 9,929 | 9,029 | $39K | |
| 80341 | 13,273 | 11,143 | $38K | |
| 80371 | 9,739 | 8,885 | $36K | |
| 83992 | 23,584 | 17,759 | $35K | |
| 80357 | 20,845 | 15,635 | $32K | |
| 80362 | 7,885 | 6,588 | $31K | |
| 80299 | 1,756 | 1,625 | $18K | |
| 80349 | 5,485 | 4,583 | $17K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 70 | 66 | $9K |
| 80323 | 1,357 | 1,187 | $5K | |
| 80356 | 1,716 | 1,580 | $4K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 113 | 108 | $3K |
| 80332 | 1,150 | 1,009 | $2K | |
| 82525 | 269 | 250 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 33 | 32 | $1K |
| 80374 | 424 | 322 | $835.08 | |
| 80325 | 437 | 333 | $828.43 | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 659 | 610 | $744.06 |
| 80376 | 165 | 137 | $702.73 | |
| 80369 | 763 | 740 | $612.58 | |
| 80363 | 35 | 34 | $446.42 | |
| 80171 | 29 | 29 | $383.15 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 14 | 14 | $356.75 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 14 | 14 | $356.75 |
| 80173 | 31 | 30 | $302.26 | |
| 80345 | 384 | 338 | $257.44 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 386 | 372 | $51.15 |
| 80375 | 344 | 261 | $48.45 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 285 | 278 | $39.78 |
| 80053 | Comprehensive metabolic panel | 273 | 262 | $28.38 |
| 84481 | 254 | 251 | $22.77 | |
| 84439 | 241 | 238 | $12.12 | |
| 86592 | 647 | 602 | $5.73 | |
| 81003 | 72 | 72 | $3.01 | |
| 87070 | 13 | 12 | $0.00 | |
| 87081 | 88 | 85 | $0.00 | |
| 83520 | 100 | 100 | $0.00 | |
| 86141 | 106 | 104 | $0.00 | |
| 80061 | Lipid panel | 175 | 170 | $0.00 |
| 84460 | 96 | 91 | $0.00 | |
| 84681 | 205 | 203 | $0.00 | |
| 82565 | 96 | 91 | $0.00 | |
| 84550 | 135 | 134 | $0.00 | |
| 84450 | 95 | 90 | $0.00 | |
| 84403 | 24 | 24 | $0.00 | |
| 80076 | 13 | 13 | $0.00 |